President Cyril Ramaphosa says the success of the groundbreaking HIV prevention drug, Lenacapavir, will depend heavily on education, individual responsibility and actively ending social stigma.
Addressing a crowd at the official rollout event in Secunda, Mpumalanga on Friday, Ramaphosa cautioned that the long-acting injectable is not a silver bullet in the fight against HIV/AIDS, but rather one more powerful tool in the government’s medical arsenal.
READ: HIV treatment and prevention advances bring hope of ending daily pills
Lenacapavir is administered as a twice-yearly shot to prevent transmission.
Meanwhile, the Health Ministry has allayed public concerns over the country's initially limited supply of the new prevention injection.
South Africa has secured just under 900,000 doses so far, which is enough to provide approximately 400,000 people with the six-monthly shot.
Health Minister Aaron Motsoaledi confirmed that the government is already moving to secure licensing agreements that could open the door for local companies to manufacture cheaper generic versions, massively expanding public access.
Motsoaledi explained that the state will soon invite pharmaceutical companies to bid for generic production, though the regulatory approval process will take some time.
"So yesterday, I phoned SAHPRA [South African Health Products Regulatory Authority]," Motsoaledi said. "They said they received all the documents; it will take them about six months to go through them. After that, if they approve them, the generic will roll out. Well, Mr President, that’s science, not me."
The Health Minister believes that breaking down these regulatory barriers will significantly reduce costs and broaden access to what many global health experts have described as an absolute game-changer for HIV prevention.